Survivin promotes cell proliferation and inhibits apoptosis,[3, 6–9] facilitates angiogenesis in tumors,[10–12] and its expression has been shown to strongly correlate with multiple mechanisms of drug resistance.[13–15] Therefore, survivin is widely considered to be an ideal cancer drug target. This evidence concerns the gene BIRC5 and cancer.